List view / Grid view
Drug Target Review’s Ria Kakkad recently travelled to Barcelona to attend PEGS Europe’s Protein and Antibody Engineering Summit. In this article, she shares her highlights from the event.
Urea cycle disorders affect the liver’s ability to excrete urea from the body. To test potential therapeutics requires an accurate model – a hurdle that has now been successfully navigated thanks to a team of researchers in Switzerland.
The new study used cryo-electron microscopy to visualise the structure of a HAT protein and uncover compounds for drug development.
The antihypertensive drug candesartan cilexetil reduced matrisomal protein accumulation in mice with cerebral small vessel disease.
Researchers used advanced microscopy and proteomics to unveil new findings on Huntington's disease and open avenues to future treatments.
Scientists have found that Hutchinson-Gilford Progeria Syndrome (HGPS) can be prevented with treatments targeting the cardiovascular system using a novel mouse model.
A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.
A new study has identified a key protein on the surface of the hepatitis C virus that interacts with a receptor found on human cells.
Interleukin 13 receptor alpha 2 was found in increased rates in cancer cells that metastasised to the brain and lungs, a new study has shown.
A new study found that protein phosphatase 2 (PP2A) found to be a major driver of preeclampsia, potentially leading to treatments.
New research has uncovered a mechanism underlying cardiac hypertrophy in mice, spurring novel avenues for potential treatments.
Inter-alpha inhibitor proteins (IAIP) demonstrated efficiency in reducing damage from an ischemic stroke, reveals pre-clinical study.
Study reveals that the HSP27 protein plays a role in regulating blood vessel leakage, providing new targets for drugs against sepsis.
Scientists unveiled how a DNA repair protein may prevent Huntington’s disease, presenting a new target in future therapies.
Researchers have revealed that the protein APOL3 acts as a detergent in human cells, potentially leading to new antibacterial treatments.
